Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer's Disease and SMA Show Clinical and Commercial Potential

  • ID: 4480189
  • Report
  • Region: Global
  • 199 pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AveXis
  • Celgene
  • Eisai
  • Forest
  • Merz
  • Pfizer
  • MORE

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies.

Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities.

It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse and exhibit specific pathophysiologies and etiologies, while affecting people of all ages.

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the five most prevalent neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD).

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates.

MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic and has a lucrative pharmacological market following breakthrough success in the past decade. Recent approvals for Ocrevus and Tecfidera are expected to sustain the market in the near future.

Scope

  • Unmet need is extremely high in AD, PD, ALS and HD, but MS and spinal muscular atrophy (SMA) show continued promise in the development of effective therapies
  • What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD, MS, ALS and HD?
  • What is the current treatment algorithm?
  • How effective are current therapies for these indications and how does this impact prognosis?
  • The neurodegenerative disease pipeline is large. Does the current pipeline innovation hold the potential to change the market over the forecast period?
  • Which molecule types and molecular targets are most prominent across the five key indications?
  • What is the risk of a neurodegenerative drug failing to make the market?
  • What is the risk of a drug failing at a specific phase, molecular target class and indication?
  • The neurodegenerative disease market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions.
  • What strategies have these companies adopted to achieve market growth?
  • Which of the leading companies will have the highest market share by 2023?
  • Which pipeline products are forecast to achieve the highest revenues on the market by 2023?
  • The deals landscape is active and dominated by immunomodulator products
  • Which indications attract the highest deal values?
  • How has deal activity fluctuated over the past decade?
  • How do deal frequency and value compare between target families and molecule types?

Reasons to buy

  • Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
  • Identify leading products and key unmet needs within the market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target. This review also provides a detailed look at clinical trials, providing an insight into the risk associated with bringing neurodegenerative disease drugs to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to the market in the near future, including sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies are on revenues derived from the neurodegenerative market. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Consider the licensing and co-development deal landscape for neurodegenerative disease drugs.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AveXis
  • Celgene
  • Eisai
  • Forest
  • Merz
  • Pfizer
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.1.1 Alzheimer’s Disease
2.1.2 Parkinson’s Disease
2.1.3 Multiple Sclerosis
2.1.4 Huntington’s Disease
2.1.5 Amyotrophic Lateral Sclerosis
2.2 Symptoms
2.3 Diagnosis
2.3.1 Alzheimer’s Disease
2.3.2 Parkinson’s Disease
2.3.3 Multiple Sclerosis
2.3.4 Huntington’s Disease
2.3.5 Amyotrophic Lateral Sclerosis
2.4 Etiology and Pathophysiology
2.4.1 Alzheimer’s Disease
2.4.2 Parkinson’s Disease
2.4.3 Multiple Sclerosis
2.4.4 Huntington’s Disease
2.4.5 Amyotrophic Lateral Sclerosis
2.5 Epidemiology
2.5.1 Alzheimer’s Disease
2.5.2 Parkinson’s Disease
2.5.3 Multiple Sclerosis
2.5.4 Huntington’s Disease
2.5.5 Amyotrophic Lateral Sclerosis
2.6 Prognosis and Disease Staging
2.6.1 Alzheimer’s Disease
2.6.2 Parkinson’s Disease
2.6.3 Multiple Sclerosis
2.6.4 Huntington’s Disease
2.6.5 Amyotrophic Lateral Sclerosis
2.7 Treatment
2.7.1 Alzheimer’s Disease
2.7.2 Parkinson’s Disease
2.7.3 Multiple Sclerosis
2.7.4 Huntington’s Disease
2.7.5 Amyotrophic Lateral Sclerosis

3 Key Marketed Products
3.1 Overview
3.2 Current and Future Trends in the MS Market
3.3 Copaxone (glatiramer acetate) - Teva
3.4 Tecfidera (dimethyl fumarate) - Biogen
3.5 Gilenya (fingolimod) - Novartis
3.6 Avonex (Interferon beta-1a) - Biogen
3.7 Tysabri (natalizumab) - Biogen
3.8 Ocrevus (ocrelizumab) - F. Hoffmann-La Roche Ltd.
3.9 Namenda/Ebixa/Axura/Abixa Memary (memantine hydrochloride) - Merz/Lundbeck/Forest/Daiichi/ Sankyo
3.10 Aricept (donepezil) - Eisai/Pfizer
3.11 Azilect (rasagiline mesylate) -Teva
3.12 Neupro (rotigotine) - UCB
3.13 Radicut (edaravone) - Mitsubishi Tanabe Pharma Corp
3.14 Xenazine (tetrabenazine) - Valeant Pharmaceuticals International Inc.
3.15 Spinraza (nusinersen) - Biogen

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.2.1 Neurodegenerative Disease Overall
4.2.2 Key Neurodegenerative Disease Indications
4.3 Molecular Targets in the Pipeline
4.3.1 Neurodegenerative Disease Overall
4.3.2 Key Neurodegenerative Disease Indications
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecular Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecular Type and Molecular Target
4.5 Assessment of Key Pipeline Products
4.5.1 Aducanumab - Biogen/Eisai
4.5.2 Azeliragon - vTv Therapeutics
4.5.3 ChariSMA - AveXis
4.5.4 Omaveloxolone - Reata Pharmaceuticals
4.5.5 Siponimod - Novartis
4.5.6 Ozanimod - Celgene
4.5.7 Elenbecestat - Eisai
4.5.8 BAN-2401 - Sage Therapeutics
4.5.9 IONIS-HTTRx
4.6 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Neuromodulators
5.3.2 Immunomodulators
5.3.3 Stress-related Targets
5.3.4 Protein Misfolding Targets
5.3.5 Neuroprotectants

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Biogen - Aducanumab and Tecfidera Cement Biogen as the Market Leader
6.1.2 Roche - Increasing Sales of Ocrevus to Drive Market Size
6.1.3 Novartis - Gradual Decline in Revenue due to Gilenya Patent Expiration Offset by Large Pipeline
6.1.4 Teva - Gradual Decline in Revenue due to Patent Expiration of Premium Product Copaxone
6.1.5 Eisai - Elenbecestat and BAN-2401 Driving New Market Growth for Eisai
6.1.6 Sanofi - Aubagio and Lemtrada on Course for Blockbuster Status in 2023
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
6.3.1 Conclusion

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type and Molecular Target
7.1.5 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Mechanism of Action and Value
7.2.5 Table for Co-development Deals Valued Above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-Filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Disease List
8.4.1 Alzheimer’s disease
8.4.2 Parkinson’s disease
8.4.3 Multiple sclerosis
8.4.4 Amyotrophic lateral sclerosis
8.4.5 Huntington’s disease
8.4.6 Other
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Disclaimer

List of Tables
Table 1: Neurodegenerative Disease Drugs Market, Symptoms of AD, PD, MS, HD and ALS, 2017
Table 2: Neurodegenerative Disease Drugs Market, Global, Epidemiology, 2017
Table 3: Neurodegenerative Disease Drugs Market, Global, Alzheimer’s Disease Neurological Tests and Disease Staging, 2017
Table 4: Neurodegenerative Disease Drugs Market, Global, Parkinson’s Disease UPRDS Scale, 2017
Table 5: Neurodegenerative Disease Drugs Market, Global, Parkinson’s Disease Revised Hoehn and Yahr Scale, 2017
Table 6: Neurodegenerative Disease Drugs Market, Global, Huntington’s Disease Unified Huntington’s Disease Rating Scale, 2017
Table 7: Neurodegenerative Disease Drugs Market, Global, Huntington’s Disease Shoulson and Fahn Staging Scale, 2017
Table 8: Neurodegenerative Disease Drugs Market, Global, Amyotrophic Lateral Sclerosis King's Method, 2017
Table 9: Neurodegenerative Disease Drugs Market, Global, Treatment Options Available for Parkinson’s Disease, 2017
Table 10: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Copaxone, 2018
Table 11: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tecfidera, 2018
Table 12: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Gilenya, 2018
Table 13: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Avonex, 2018
Table 14: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tysabri, 2018
Table 15: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Ocrevus, 2018
Table 16: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Namenda/Ebixa/Axura/Abixa/Memary, 2018
Table 17: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Aricept, 2018
Table 18: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Azilect, 2018
Table 19: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Neupro, 2018
Table 20: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Radicut 2018
Table 21: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Xenazine, 2018
Table 22: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Spinraza, 2018
Table 23: Neurodegenerative Disease Drugs Market, Global, Usage of Generics Across Key Indications, 2018

List of Figures
Figure 1: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Alzheimer’s Disease, 2016-2023
Figure 2: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Parkinson’s Disease, 2016-2023
Figure 3: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Multiple Sclerosis, 2016-2023
Figure 4: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Huntington’s Disease, 2016-2023
Figure 5: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Amyotrophic Lateral Sclerosis, 2016-2023
Figure 6: Neurodegenerative Disease Drugs Market, Global, Multiple Sclerosis Disease Profiling, 2017
Figure 7: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Key Players, 2006-2023
Figure 8: Neurodegenerative Disease Drugs Market, Global, Market Share of Copaxone, Tecfidera, Gilenya, Avonex, Tysabri and Ocrevus Within MS, 2006-2023
Figure 9: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Copaxone ($bn), 2006-2023
Figure 10: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tecfidera, 2013-2023
Figure 11: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Gilenya, 2011-2023
Figure 12: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Avonex, 2006-2023
Figure 13: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tysabri, 2006-2023
Figure 14: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Ocrevus, 2017-2023
Figure 15: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Namenda/ Ebixa/ Axura/ Abixa/ Memary, 2006-2023
Figure 16: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Aricept, 2006-2023
Figure 17: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Azilect, 2006-2023
Figure 18: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Neupro, 2006-2023
Figure 19: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Radicut, 2006-2023
Figure 20: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Xenazine, 2006-2023
Figure 21: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Spinraza ($bn), 2016-2023
Figure 22: Neurodegenerative Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 23: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 24: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Stage of Development, 2018
Figure 25: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecule Type, 2018
Figure 26: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development and Molecular Target, 2018
Figure 27: Neurodegenerative Disease Drugs Market, Global, Pipeline by Molecular Target, 2018
Figure 28: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecular Target, 2018
Figure 29: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2018
Figure 30: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018
Figure 31: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018
Figure 32: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018
Figure 33: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
Figure 34: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018
Figure 35: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018
Figure 36: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018
Figure 37: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006-2018
Figure 38: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2017
Figure 39: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2018
Figure 40: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2018
Figure 41: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development, 2006-2018
Figure 42: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2018
Figure 43: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2018
Figure 44: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2017
Figure 45: Neurodegenerative Disease Drugs Market, Global, Revenue for Aducanumab ($bn), 2020-2023
Figure 46: Neurodegenerative Disease Drugs Market, Global, Revenue for Azeliragon ($bn), 2019-2023
Figure 47: Neurodegenerative Disease Drugs Market, Global, Revenue for ChariSMA ($bn), 2019-2023
Figure 48: Neurodegenerative Disease Drugs Market, Global, Revenue for Omaveloxolone ($bn), 2019-2023
Figure 49: Neurodegenerative Disease Drugs Market, Global, Revenue for Siponimod ($bn), 2019-2023
Figure 50: Neurodegenerative Disease Drugs Market, Global, Revenue for Ozanimod ($bn), 2018-2023
Figure 51: Neurodegenerative Disease Drugs Market, Global, Revenue for Elenbecestat ($m), 2020-2023
Figure 52: Neurodegenerative Disease Drugs Market, Global, Revenue for BAN-2401 ($m), 2020-2023
Figure 53: Neurodegenerative Disease Drugs Market, Global, Revenue for IONIS-HTTRx ($m), 2020-2023
Figure 54: Neurodegenerative Disease Drugs Market, Global, Market Size ($bn), 2016-2023
Figure 55: Neurodegenerative Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
Figure 56: Neurodegenerative Disease Drugs Market, Global, Key Products Market Share, 2016-2023
Figure 57: Neurodegenerative Disease Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
Figure 58: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuromodulators ($bn), 2016-2023
Figure 59: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Immunomodulators ($bn), 2016-2023
Figure 60: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Stress-related inhibitors ($bn), 2016-2023
Figure 61: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Protein Misfolding and Aggregation Inhibitors ($bn), 2016-2023
Figure 62: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuroprotectants ($bn), 2016-2023
Figure 63: Neurodegenerative Disease Drugs Market, Global, Company Analysis Matrix, 2016-2023
Figure 64: Neurodegenerative Disease Drugs Market, Global, Cluster Graph by Growth and Market Share, 2016-2023
Figure 65: Neurodegenerative Disease Drugs Market, Global, Forecast Revenue by Company, 2016-2023
Figure 66: Neurodegenerative Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 67: Neurodegenerative Disease Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 68: Neurodegenerative Disease Drugs Market, Global, Revenue by Product Type, 2016-2023
Figure 69: Neurodegenerative Disease Drugs Market, Global, Biogen Annual Revenue Forecast ($bn), 2016-2023
Figure 70: Neurodegenerative Disease Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
Figure 71: Neurodegenerative Disease Drugs Market, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
Figure 72: Neurodegenerative Disease Drugs Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
Figure 73: Neurodegenerative Disease Drugs Market, Global, Eisai Annual Revenue Forecast ($bn), 2016-2023
Figure 74: Neurodegenerative Disease Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016-2023
Figure 75: Neurodegenerative Disease Drugs Market, Global, Companies by Type, 2018
Figure 76: Neurodegenerative Disease Drugs Market, Global, High-Activity and Late-Stage Developers by Level of Neurodegenerative Specialization, 2018
Figure 77: Neurodegenerative Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2016-2023
Figure 78: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006-2018
Figure 79: Neurodegenerative Disease Drugs Market, Global, Licensing Deal Volume and Value by Indication, 2006-2018
Figure 80: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018
Figure 81: Neurodegenerative Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2018
Figure 82: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006-2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AveXis
  • Biogen
  • Celgene
  • Daiichi
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • Forest
  • Lundbeck
  • Merz
  • Mitsubishi Tanabe Pharma Corp
  • Novartis
  • Pfizer
  • Reata Pharmaceuticals
  • Sage Therapeutics
  • Sankyo
  • Teva
  • UCB
  • Valeant Pharmaceuticals International Inc.
  • vTv Therapeutics
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll